#2: Sirtris Announces SRT501 Lowers Glucose in Twice-Daily Dosing Clinical Trial; Study Suggests Dose Response for Proprietary Formulation of Resveratrol in Type 2 Diabetics
Sirtris Announces SRT501 Lowers Glucose in Twice-Daily Dosing Clinical Trial; Study Suggests Dose Response for Proprietary Formulation of Resveratrol in Type 2 Diabetics
Clinical Trial Further...
#1: Sirtris Pharmaceuticals to Present at the ThinkEquity 5th Annual Growth Conference and Bank of America 37th Annual Investment Conference on September 18, 2007
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT stock forums), a biopharmaceutical
company focused on discovering and developing small molecule drugs to
treat diseases of aging such...
